All In Biotech

Drug Trial Radar · NCT07947368

Study to Evaluate the Effect of Crinecerfont on Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia (CAH)

A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the effect of crinecerfont on elevated androstenedione levels in adults with classic CAH on a stable glucocorticoid (GC) dose.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • CrinecerfontDrug

    Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Serum Androstenedione at Week 24Time frame: Baseline, Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.